| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Drotaverine (INN, also known as drotaverin) is an antispasmodic drug, structurally related to papaverine. Drotaverine is a selective inhibitor of phosphodiesterase 4, and has no anticholinergic effects. Drotaverine has been shown to possess dose-dependant analgesic effects in animal models. One small study has shown drotaverine to be eliminated mainly non-renally. |
| Indication |
Used in the treatment of functional bowel disorders and alleviating pain in renal colic. |
| Pharmacology |
Drotaverine is a spasmolytic agent by inhibiting PDE4 in smooth muscle cells. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic |
| Absorption |
Bioavailability is highly variable |
| Half Life |
7 to 12 hours |
| Protein Binding |
80 to 95% |
| References |
| • |
Bolaji OO, Onyeji CO, Ogundaini AO, Olugbade TA, Ogunbona FA: Pharmacokinetics and bioavailability of drotaverine in humans. Eur J Drug Metab Pharmacokinet. 1996 Jul-Sep;21(3):217-21.
[Pubmed]
|
|
| External Links |
|